Analytical Data
-
Gene name
GAT1
- Application
-
Alternative Names
GABATR; GABT1; GAT1
-
Species
Human
-
Source
HEK293
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P30531
-
Expression Region
M1-I599
-
Protein Length
Full Length
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GAT1, also known as the GABA transporter 1, is a critical protein in the central nervous system that is responsible for the reuptake of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the brain. The regulation of GABA levels is essential for maintaining the balance between excitation and inhibition in neuronal signaling, making GAT1 a significant target for the treatment of various neurological disorders, including epilepsy, anxiety, and depression. Understanding the structure and function of GAT1 at the molecular level can provide insights into its role in synaptic transmission and help identify new therapeutic strategies. Recent advances in recombinant protein technology have enabled researchers to produce and purify GAT1 extensively, facilitating the investigation of its biophysical properties and interaction with pharmacological agents. These studies are critical for elucidating the mechanisms of GABA transport and identifying potential drug candidates that could modulate GAT1's activity, thereby offering new avenues for drug development to address GABAergic dysfunctions in various psychiatric and neurological conditions. As a result, the research into GAT1 recombinant proteins not only plays a vital role in basic neuroscience but also has significant implications for therapeutic interventions targeting neurotransmitter systems in the brain.
